X Genomics Inc (TXG) stock saw a decline, ending the day at $14.9 which represents a decrease of $-1.41 or -8.65% from the prior close of $16.31. The stock opened at $16.1 and touched a low of $14.19 ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and competition warrant a Sell rating.

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from Bank of America Securities maintained a Hold rating on ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Stifel Nicolaus analyst Daniel Arias has maintained their bullish stance on TXG stock, giving a Buy rating yesterday.Stay Ahead of the ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

X Genomics Inc (TXG) stock saw a decline, ending the day at $15.08 which represents a decrease of $-0.01 or -0.07% from the prior close of $15.09. The stock opened at $15.46 and touched a low of $14.9 ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2024.